Consistent with this, in 44 ALK+ and ALK− ALCL tumor samples, 82% were SHP-1 negative by immunohistochemistry, and this was frequently as a result of methylation of the SHP-1 promoter [52]. The gene discussed is ALK; the disease is neoplasm.